Compare Nvidia Corp (NVDA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nvidia Corp trades at $206.61 (market cap $4.92T), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Nvidia Corp is far larger — about 3215.7× Recursion Pharmaceuticals Inc's market cap, and Nvidia Corp pays a 0.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NVDA | RXRX | |
|---|---|---|
Market Cap | $4.92T | $1.53B |
Sector | Technology | Health |
52-Week High | $235.75 | $6.79 |
52-Week Low | $165.17 | $2.84 |
Enterprise Value | $4.86T | $946.50M |
Dividend Yield | 0.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.
Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
